- Home
- PLD vs BMY Comparison
PLD vs BMY Comparison
Compare PLD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLD
- BMY
- Stock Information
- Founded
- PLD 1983
- BMY 1887
- Country
- PLD United States
- BMY United States
- Employees
- PLD N/A
- BMY N/A
- Industry
- PLD Real Estate Investment Trusts
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- PLD Real Estate
- BMY Health Care
- Exchange
- PLD Nasdaq
- BMY Nasdaq
- Market Cap
- PLD 105.6B
- BMY 94.0B
- IPO Year
- PLD 1994
- BMY N/A
- Fundamental
- Price
- PLD $124.46
- BMY $45.98
- Analyst Decision
- PLD Buy
- BMY Hold
- Analyst Count
- PLD 17
- BMY 14
- Target Price
- PLD $123.67
- BMY $57.54
- AVG Volume (30 Days)
- PLD 3.5M
- BMY 16.4M
- Earning Date
- PLD 10-15-2025
- BMY 10-30-2025
- Dividend Yield
- PLD 3.25%
- BMY 5.39%
- EPS Growth
- PLD 3.74
- BMY N/A
- EPS
- PLD 3.43
- BMY 2.97
- Revenue
- PLD $9,100,544,000.00
- BMY $48,034,000,000.00
- Revenue This Year
- PLD $1.91
- BMY N/A
- Revenue Next Year
- PLD $6.71
- BMY N/A
- P/E Ratio
- PLD $36.17
- BMY $15.48
- Revenue Growth
- PLD 10.45
- BMY 1.26
- 52 Week Low
- PLD $85.35
- BMY $42.52
- 52 Week High
- PLD $127.50
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- PLD 60.01
- BMY 59.11
- Support Level
- PLD $122.55
- BMY $42.52
- Resistance Level
- PLD $124.92
- BMY $45.23
- Average True Range (ATR)
- PLD 2.68
- BMY 0.90
- MACD
- PLD -0.24
- BMY 0.33
- Stochastic Oscillator
- PLD 72.34
- BMY 83.45
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.